A new drug with the potential to treat endometriosis-associated pain with very few side effects is getting closer to official approval.
It might not be long until officials also consider the drug as a treatment for people with endometriosis.when using linzagolix to treat women with moderate-to-severe endometriosis-associated pain. The findings from their phase-3 clinical trial have not yet been peer-reviewed, so they need to be taken with a grain of salt. But preliminary results are encouraging – hopefully we'll have more details soon.
With the higher dose, patients were also given an"add-back" hormonal therapy, as linzagolix works on the brain to reduce estrogen production in the ovaries. of taking linzagolix, impacting about 20 percent of people on the low dose and nearly half of those on the high dose."no clinically significant impact on bone mineral density", while the high-dose only showed minimal loss.
"Once daily linzagolix 200 mg with add-back therapy demonstrated excellent efficacy along with minimal changes in bone mineral density, suggesting this dose may be used for long-term treatment."
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Origins of Drug-Resistant Superbug Weren't What We Thought, Surprise Discovery ShowsAn evolutionary battle between fungi and bacteria on hedgehogs' skin gave rise to a type of antibiotic-resistant bacteria long before humans started using the antibiotics that were thought to lead to such superbugs, a new study reveals.
Baca lebih lajut »
Why Biogen's Alzheimer's drug Aduhelm is so controversialThe FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm in June was heralded as a historic triumph. But the excitement around the drug has receded. Why is Biogen’s drug so controversial? Watch the full video here:
Baca lebih lajut »
Happy new year? Drug prices rising as 2022 beginsGoodRx, a healthcare company that tracks prescription drug prices in the United States, reports that prices for 442 drugs have increased by an average 5.2% already this year.
Baca lebih lajut »